AXSM on Nasdaq
Axsome Therapeutics
American biopharmaceutical company.1
Price unavailable
Last updated Oct 16, 2026.
Overview
2012Founded1
Compare with Amicus Therapeutics, Legend Biotech or TG Therapeutics, or pick any stock.
- TickerAXSM on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersNew York City1
- Websiteaxsome.com
- Incorporated inDE3
- Business addressOne World Trade Center, 29Th Floor, New York, Ny 100073
- Filer categoryLarge accelerated filer3
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-26.1%Operating margin5
-28.7%Net margin5
65.5%Revenue growth, 20255
-207.5%Return on equity5
1.33×Debt to equity5
-$93.9MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 99% of the revenue Axsome Therapeutics broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product | $202.5M | $381.7M | $633.8M |
| Royalty and Milestone Revenue | $2.4M | $4.0M | $4.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development24¢$183.3M
- Selling, general and admin74¢$570.6M
- Interest2¢$15.9M
- Income tax0¢$530.0K
Out of $638.5M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $638.5M | $385.7M | $270.6M |
| Cost of revenue (excluding amortization and depreciation) | $47.5M | $33.3M | $26.1M |
| Research and development | $183.3M | $187.1M | $97.9M |
| Selling, general and administrative | $570.6M | $411.4M | $323.1M |
| Loss (Gain) in fair value of contingent consideration | -$2.5M | $28.1M | $48.9M |
| Intangible asset amortization | $6.4M | $6.4M | $6.4M |
| Total operating expenses | $805.3M | $666.3M | $502.4M |
| Loss from operations | -$166.8M | -$280.6M | -$231.8M |
| Interest expense, net | -$6.6M | -$6.6M | -$6.5M |
| Loss on debt extinguishment | -$10.4M | ||
| Loss before income taxes | -$183.7M | -$287.1M | -$238.3M |
| Income tax benefit (expense) | $530.0K | -$85.0K | -$960.0K |
| Net loss | -$183.2M | -$287.2M | -$239.2M |
| Net loss per common share, basic | -$3.68 | -$5.99 | -$5.27 |
| Net loss per common share, diluted | -$3.68 | -$5.99 | -$5.27 |
| Weighted average common shares outstanding, basic | 49.7M shares | 47.9M shares | 45.4M shares |
| Weighted average common shares outstanding, diluted | 49.7M shares | 47.9M shares | 45.4M shares |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $322.9M | $315.4M | |
| Accounts receivable, net | $224.5M | $142.0M | |
| Inventories, net | $27.9M | $15.7M | |
| Prepaid and other current assets | $13.7M | $12.0M | |
| Total current assets | $589.0M | $485.1M | |
| Equipment, net | $562.0K | $584.0K | |
| Right-of-use asset | $20.9M | $5.4M | |
| Goodwill | $12.0M | $12.0M | |
| Intangible asset, net | $40.5M | $46.9M | |
| Non-current inventory and other assets | $26.8M | $18.5M | |
| Total assets | $689.8M | $568.5M | |
| Accounts payable | $65.5M | $72.0M | |
| Accrued expenses and other current liabilities | $232.9M | $148.0M | |
| Operating lease liability, current portion | $434.0K | $1.8M | |
| Contingent consideration, current | $10.0M | $8.3M | |
| Short-term borrowings | $70.0M | $0 | |
| Total current liabilities | $378.8M | $230.1M | |
| Contingent consideration, non-current | $77.5M | $91.7M | |
| Loan payable, long-term | $117.7M | $180.7M | |
| Operating lease liability, long-term | $23.2M | $6.0M | |
| Finance lease liability, long-term | $4.2M | $2.9M | |
| Total liabilities | $601.5M | $511.5M | |
| Common stock, $0.0001 par value per share (150,000,000 shares authorized, 50,882,766 and 48,667,587 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively) | $5.0K | $5.0K | |
| Additional paid-in capital | $1.4B | $1.2B | |
| Accumulated deficit | -$1.3B | -$1.1B | |
| Total stockholders equity | $88.3M | $57.0M | $191.0M |
| Total liabilities and stockholders equity | $689.8M | $568.5M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 150.0M shares | 150.0M shares | |
| Common stock, shares issued | 50.9M shares | 48.7M shares | |
| Common stock, shares outstanding | 50.9M shares | 48.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$183.2M | -$287.2M | -$239.2M |
| Stock-based compensation expense | $93.8M | $85.2M | $62.6M |
| Amortization of intangible asset | $6.4M | $6.4M | $6.4M |
| Amortization of debt discount | $1.3M | $2.6M | $2.6M |
| Loss on debt extinguishment | $10.4M | ||
| Depreciation | $503.0K | $532.0K | $459.0K |
| Loss in fair value of contingent consideration | -$2.5M | $28.1M | $48.9M |
| Gain from lease modification | -$2.2M | ||
| Non-cash lease expense | $3.0M | $1.4M | $1.4M |
| Right-of-use asset amortization for finance lease | $2.2M | $1.0M | |
| Accounts receivable, net | -$82.5M | -$47.2M | -$57.1M |
| Inventories, net | -$10.7M | $744.0K | -$8.2M |
| Prepaid expenses and other current assets | -$1.7M | -$3.9M | -$5.3M |
| Non-current inventory and other assets | -$5.0M | -$3.2M | $3.7M |
| Accounts payable | -$6.5M | $31.3M | $2.1M |
| Accrued expenses and other current liabilities | $83.7M | $56.1M | $36.5M |
| Operating lease liability | -$535.0K | -$422.0K | $154.0K |
| Net cash used in operating activities | -$93.4M | -$128.4M | -$145.1M |
| Purchases of equipment | -$480.0K | -$270.0K | -$582.0K |
| Net cash used in investing activities | -$480.0K | -$270.0K | -$582.0K |
| Proceeds from draw down of debt | $330.0M | $85.0M | |
| Payment of debt issuance costs | -$3.6M | -$1.4M | |
| Repayment of debt | -$332.0M | ||
| Payments on principal portion of finance lease obligation | -$2.1M | -$990.0K | |
| Proceeds from issuance of common stock upon financing | $67.9M | $40.8M | $258.8M |
| Cash paid for common stock issuance costs | -$1.2M | -$816.0K | -$15.7M |
| Proceeds from issuance of common stock upon exercise of options and under employee stock purchase plan | $59.6M | $30.7M | $12.4M |
| Payment of contingent consideration | -$9.9M | -$7.9M | -$6.2M |
| Payments of tax withholdings on stock awards | -$7.1M | -$4.0M | -$1.8M |
| Net cash provided by financing activities | $101.5M | $57.8M | $331.0M |
| Net increase (decrease) in cash | $7.6M | -$70.8M | $185.4M |
| Interest paid | $14.6M | $19.7M | $16.7M |
| Operating lease right-of-use asset obtained in exchange for operating lease liability | $23.9M | $7.8M | |
| Finance lease right-of-use asset obtained in exchange for finance lease liability | $4.5M | $5.4M | |
| Decrease in operating lease right-of-use asset due to lease modification | $5.3M | ||
| Decrease in operating lease liability due to lease modification | $7.6M | ||
| Issuance of warrants in connection with debt financing | $1.6M |
Timeline
- 2012Founded Founded1
Recent filings
- Sep 3, 2026144
- Sep 3, 20264
- Aug 10, 20268-K
- Aug 10, 202610-Q
- Aug 7, 20264
- Aug 6, 2026144
- Aug 5, 2026144
- Jul 27, 2026SCHEDULE 13G/A
- Jul 15, 20268-K
- Jul 1, 2026144
- Jul 1, 20264
- Jun 11, 2026144
- Jun 11, 20264
- Jun 10, 2026144
- Jun 10, 2026144
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websiteaxsome.com1
- X (Twitter)x.com/axsome1
- LinkedInwww.linkedin.com/company/axsome-therapeutics-inc-1
- WikidataQ104480012
- SEC EDGARCIK 1579428
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataAxsome Therapeutics on Wikidata
- 2
- 3
- 4Company websiteAxsome Therapeutics photo
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12